A detailed history of Perfromance Wealth Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Perfromance Wealth Partners, LLC holds 33,948 shares of ABBV stock, worth $6.01 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
33,948
Previous 34,764 2.35%
Holding current value
$6.01 Million
Previous $5.96 Million 12.45%
% of portfolio
0.23%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$163.84 - $199.33 $133,693 - $162,653
-816 Reduced 2.35%
33,948 $6.7 Million
Q2 2024

Jul 19, 2024

SELL
$154.79 - $180.76 $232,958 - $272,043
-1,505 Reduced 4.15%
34,764 $5.96 Million
Q1 2024

Apr 30, 2024

SELL
$159.82 - $182.1 $332,745 - $379,132
-2,082 Reduced 5.43%
36,269 $6.6 Million
Q4 2023

Jan 22, 2024

SELL
$137.6 - $154.97 $990,857 - $1.12 Million
-7,201 Reduced 15.81%
38,351 $5.94 Million
Q3 2023

Oct 30, 2023

SELL
$133.59 - $154.65 $227,370 - $263,214
-1,702 Reduced 3.6%
45,552 $6.79 Million
Q2 2023

Jul 13, 2023

BUY
$132.51 - $164.9 $54,726 - $68,103
413 Added 0.88%
47,254 $6.37 Million
Q1 2023

Apr 20, 2023

SELL
$144.61 - $166.54 $3,470 - $3,996
-24 Reduced 0.05%
46,841 $7.47 Million
Q4 2022

Jan 19, 2023

SELL
$138.31 - $165.87 $588,923 - $706,274
-4,258 Reduced 8.33%
46,865 $0
Q3 2022

Oct 17, 2022

SELL
$134.21 - $153.93 $10,468 - $12,006
-78 Reduced 0.15%
51,123 $6.86 Million
Q2 2022

Jul 15, 2022

SELL
$137.62 - $174.96 $418,227 - $531,703
-3,039 Reduced 5.6%
51,201 $7.84 Million
Q1 2022

Apr 21, 2022

BUY
$131.98 - $163.75 $26,264 - $32,586
199 Added 0.37%
54,240 $8.79 Million
Q4 2021

Feb 03, 2022

BUY
$107.43 - $135.93 $5.81 Million - $7.35 Million
54,041 New
54,041 $7.32 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Perfromance Wealth Partners, LLC Portfolio

Follow Perfromance Wealth Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perfromance Wealth Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perfromance Wealth Partners, LLC with notifications on news.